更新于：2024-11-07
Penehyclidine hydrochloride
盐酸戊乙奎醚
更新于：2024-11-07
概要
基本信息
原研机构 |
非在研机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C20H30ClNO2 |
InChIKeyDDTVVMRZNVIVQM-UHFFFAOYSA-N |
CAS号151937-76-7 |
关联
37
项与 盐酸戊乙奎醚 相关的临床试验Inhaling Penehyclidine to Prevent Perioperative Respiratory Adverse Events in Children at Risk Undergoing Minor Elective Surgery
Penehyclidine for prevention of postoperative nausea and vomiting following temporomandibular joint surgery
Effect of penehyclidine hydrochloride on postoperative nausea and vomiting in preoperative anxiety patients undergoing gynecologic outpatient surgery
100 项与 盐酸戊乙奎醚 相关的临床结果
登录后查看更多信息
100 项与 盐酸戊乙奎醚 相关的转化医学
登录后查看更多信息
100 项与 盐酸戊乙奎醚 相关的专利（医药）
登录后查看更多信息
1,283
项与 盐酸戊乙奎醚 相关的文献（医药）2024-11-01Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Prevalence, Dynamics, and Prognostic Role of Clonal Hematopoiesis of Indeterminate Potential in Patients With Breast Cancer
Article
作者: Stover, Daniel G. ; Patel, Ashka ; Mittendorf, Elizabeth A. ; King, Tari A. ; Jin, Qingchun ; Miller, Peter G. ; Stokes, Samantha ; Tayob, Nabihah ; Vincuilla, Julie ; Lin, Nancy U. ; Merrill, Margaret ; Weeks, Lachelle D. ; Wilson, Alex ; Parsons, Heather A. ; Hughes, Melissa E. ; Lipsyc-Sharf, Marla ; Morganti, Stefania ; Curigliano, Giuseppe ; Santos, Katheryn ; Garber, Judy E. ; Tolaney, Sara M. ; Gibson, Christopher J. ; Parker, Tonia
PURPOSE:
Clonal hematopoiesis of indeterminate potential (CHIP) is frequent in patients with solid tumors. Prospective data about CHIP prevalence at breast cancer diagnosis and its dynamic evolution under treatment selective pressure are limited.
PATIENTS AND METHODS:
We performed targeted error-corrected sequencing on 614 samples from 380 patients with breast cancer. We investigated the dynamics of CHIP on prospectively collected paired samples from patients with early breast cancer (eBC) receiving chemotherapy (CT) or endocrine therapy (ET). We assessed the correlation of CHIP with survival in patients with metastatic triple-negative breast cancer (mTNBC). We estimated the risk of progression to treatment-related myeloid neoplasms (t-MN) according to the clonal hematopoiesis risk score (CHRS). In exploratory analyses, we considered clonal hematopoiesis (CH) with variant allele fraction (VAF) ≥0.005.
RESULTS:
CHIP was identified in 15% of patients before treatment. Few CHIP emerged after treatment, and the risk of developing new mutations was similar for patients receiving CT versus ET (odds ratio [OR], 1.16;
P
= .820). However, CT increased the risk of developing new CH with VAF ≥0.005 (OR, 3.45;
P
= .002). Five
TP53-
mutant CH with VAF ≥0.005 emerged among patients receiving CT. Most patients had low risk of t-MN according to the CHRS score. CHIP did not correlate with survival in mTNBC.
CONCLUSION:
CHIP is frequent in patients with breast cancer. In this study, CT did not lead to emergence of new CHIP, and most patients had low risk of developing t-MN. This finding is reassuring, given long life expectancy of patients with eBC and the association of CHIP with morbidity and mortality. However,
TP53
-mutant CH with VAF ≥0.005 emerged with CT, which carries high risk of t-MN. Evolution of these small clones and their clinical significance warrant further investigation.
2024-08-01INTERNATIONAL IMMUNOPHARMACOLOGY
ZBP1-mediated PANoptosis: A possible novel mechanism underlying the therapeutic effects of penehyclidine hydrochloride on myocardial ischemia–reperfusion injury
Article
作者: Zhang, Guanzheng ; Cui, Boqun ; Lin, Duomao ; Liu, Wenjun ; Qi, Zeyou
Although penehyclidine hydrochloride (PHC) has been identified to alleviate myocardial injury induced by ischemia/reperfusion (I/R), the regulatory molecules and related mechanisms are unknown. In this study, bioinformatics, molecular biology, and biochemistry methods were used to explore the molecular mechanisms and targets of PHC. In the myocardial ischemia-reperfusion injury (MIRI)-induced rat model, PHC pretreatment significantly improved cardiac function (p < 0.01). Multiple differentially expressed genes, including Z-DNA binding protein 1 (ZBP1), were identified through mRNA sequencing analysis of myocardial ischemic penumbra tissue in MIRI rats. The transduction of the ZBP1 adenovirus vector (Ad-Zbp1) in PHC-pretreated rats exhibited a reversible augmentation in myocardial infarct size (p < 0.01), pronounced pathological damage to the myocardial tissue, as well as a significant elevation of serum myocardial enzymes (p < 0.05). The interaction among ZBP1, fas-associating via death domain (FADD), and receptor-interacting serine/threonine-protein kinase 3 (RIPK3) leads to a remarkable up-regulation of cleaved-Caspase-1 (Cl-Casp-1), N-terminal gasdermin D (N-GSDMD), phospho-mixed lineage kinase domain-like Ser358 (p-MLKLS358), and other regulatory proteins, thereby triggering pyroptosis, apoptosis, and necroptosis (PANoptosis) in cardiomyocytes of MIRI rats. Moreover, the transduction of Ad-Zbp1 in the oxygen-glucose deprivation/re-oxygenation (OGD/R)-induced H9c2 cell model also dramatically augmented the number of cell deaths. However, the intervention of PHC considerably enhanced cell viability (p < 0.01), effectively mitigated the release of myocardial enzymes (p < 0.05), and markedly attenuated the expression levels of PANoptosis regulatory proteins through restraint of ZBP1 expression. Therefore, the therapeutic efficacy of PHC in improving MIRI might be attributed to targeting ZBP1-mediated PANoptosis.
2024-08-01International journal of radiation oncology, biology, physics
Out-of-Pocket Cost Modeling of Adjuvant Antiestrogen and Radiation Therapy After Lumpectomy for Early-Stage Breast Cancer Across Medicaid and Medicare Plans
Article
作者: Jagsi, Reshma ; Khlopin, Martha ; Wu, Victoria S ; McClelland, Shearwood ; Smith-Graziani, Demetria J ; Chadha, Manjeet
PURPOSE:
The optimal adjuvant therapy (antiestrogen therapy [ET] + radiation therapy or ET alone, or in some reports radiation therapy alone) in older women with early-stage breast cancer has been highly debated. However, granular details on the role of insurance in the out-of-pocket cost for patients receiving ET with or without radiation therapy are lacking. This project disaggregates out-of-pocket costs by insurance plans to increase treatment cost transparency.
METHODS AND MATERIALS:
Several radiation therapy schedules are accepted standards as per the National Comprehensive Cancer Network guidelines. For our financial estimate model, we used the 5-fraction and 15-fraction radiation therapy and ET prescribed over a 5-year duration. The total aggregate out-of-pocket costs were determined from the sum of treatment costs, deductibles, and copays/coinsurance based on Medicaid, Original Medicare, Medigap Plan G, and Medicare Part D Rx plans. The model assumes a Medicare- and/or Medicaid-eligible patient ≥70 years of age with node-negative, early-stage estrogen-receptor-positive breast cancer. Patient out-of-pocket costs were estimated from publicly available insurance data from plan-specific benefit coverage materials using a 5-year time horizon.
RESULTS:
Original Medicare beneficiaries face a total out-of-pocket treatment charge of $2738.52 for ET alone, $2221.26 for 5-fraction radiation therapy alone, $2573.92 for 15-fraction radiation therapy alone, $3361.26 for combined ET+ 5-fraction radiation therapy, and $3713.92 for combined ET + 15-fraction radiation therapy. Medigap Plan G beneficiaries have an out-of-pocket charge of $1130.00 with radiation therapy alone and face an out-of-pocket of $2270.00 for ET alone and combined ET+ radiation therapy. For Medicaid beneficiaries, all treatments approved by Medicaid are covered without limit, resulting in no out-of-pocket expense for either adjuvant treatment option.
CONCLUSIONS:
This model (based on actual cost estimates per insurance plan rather than claims data), by estimating expenses within Medicare and Medicaid plans, provides a level of transparency to patient cost. With knowledge of the costs borne by patients themselves, treatment decisions informed by patients' individual priorities and preferences may be further enhanced.
100 项与 盐酸戊乙奎醚 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 麻醉 | 中国 | 2002-10-24 | |
| 药物中毒 | 中国 | 2002-10-24 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 胆道痛 | 临床2期 | 中国 | 2017-05-19 | |
| 胆道痉挛 | 临床2期 | 中国 | 2017-05-19 | |
| 慢性阻塞性肺疾病 | 临床2期 | 中国 | 2008-07-21 | |
| 脓毒性休克 | 临床1期 | 中国 | 2012-06-11 | |
| 帕金森病 | 临床1期 | 中国 | 2012-03-15 | |
| 休克 | 临床1期 | 中国 | 2012-03-15 | |
| 平滑肌痉挛 | 临床1期 | 中国 | 2012-03-15 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | - | 100 | 顧夢蓋鏇鹽鹹窪醖鏇醖(繭繭遞製獵艱襯構顧壓) = 襯糧鹹壓鑰夢餘壓簾蓋 積範齋壓淵淵齋壓膚鏇 (鏇願壓夢選襯範繭衊積 ) | - | 2022-10-14 | ||
TIVA group | 顧夢蓋鏇鹽鹹窪醖鏇醖(繭繭遞製獵艱襯構顧壓) = 願積顧襯觸齋獵繭積選 積範齋壓淵淵齋壓膚鏇 (鏇願壓夢選襯範繭衊積 ) | ||||||
临床3期 | - | 864 | 餘艱憲積鑰鏇蓋製遞簾(選衊遞觸範襯廠獵鏇觸) = dry mouth and delirium 觸觸壓遞齋範網獵鹹選 (鏇壓鬱鹹觸餘壓廠簾淵 ) | 积极 | 2022-04-01 | ||
Placebo | |||||||
临床4期 | 228 | 製鬱繭積遞鬱衊餘窪齋(糧糧鬱蓋積範獵網鑰襯) = 膚襯夢築膚鑰醖範淵獵 鹹鏇積製築艱簾壓築糧 (鹽淵鬱醖願糧鹽選襯夢 ) 更多 | - | 2021-02-13 | |||
製鬱繭積遞鬱衊餘窪齋(糧糧鬱蓋積範獵網鑰襯) = 艱衊憲積壓窪顧蓋構餘 鹹鏇積製築艱簾壓築糧 (鹽淵鬱醖願糧鹽選襯夢 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用